Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1977 Dec;30(3):364–369.

A study of the material inhibiting EAC-rosette formation in the sera of patients with nephropathies.

M D Smith, P J Verroust, C Adam, M Galceran, L Morel-Maroger
PMCID: PMC1541153  PMID: 606450

Abstract

Significant levels of EAC-rosette inhibition compared to control subjects were found in the sera of patients with focal and segmental hyalinosis (FSH), membranoproliferative glomerulonephritis (MPGN) and extra-membranous glomerulonephritis (EGN). In patients with IgA disease, although some sera produced high levels of inhibition, the group as a whole did not differ significantly from the controls. Evidence was obtained suggesting that the rosette inhibitory activity was due to immune complexes (IC) bearing C3 rather than C3 fragments. Firstly, the inhibitory activity was precipitable by 4% PEG, a concentration which does not precipitate the C3 fragments. Secondly, the inhibitory activity was selectively removed from the PEG precipitates by an anti-human immunoglobulin G immunoabsorbent. Finally, since it had been suggested that in some instances an unknown serum factor could inhibit EAC-rosette formation and activation of the alternative pathway of complement, the latter was studied and found to be normal in all the sera studied. Taken together, these results suggest that the inhibition of EAC-rosette formation obtained with the sera of the patients studied was due to the presence in these sera of some material behaving as IC. No clear-cut association was, however, seen between rosette inhibition and the presence or absence of Ig or C3 deposits in the kidney.

Full text

PDF
364

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnaiz-Villena A., Sheldon P. Autoimmune New Zealand mouse. Alterations in C3 receptors, complement-induced clumps and follicular adherence of immune complexes. Immunology. 1975 Dec;29(6):1103–1110. [PMC free article] [PubMed] [Google Scholar]
  2. Cuatrecasas P. Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads. J Biol Chem. 1970 Jun;245(12):3059–3065. [PubMed] [Google Scholar]
  3. Eden A., Bianco C., Nussenzweig Mechanism of binding of soluble immune complexes to lymphocytes. Cell Immunol. 1973 Jun;7(3):459–473. doi: 10.1016/0008-8749(73)90210-4. [DOI] [PubMed] [Google Scholar]
  4. Ezer G., Hayward A. R. Inhibition of complement-dependent lymphocyte rosette formation: a possible test for activated complement products. Eur J Immunol. 1974 Feb;4(2):148–150. doi: 10.1002/eji.1830040216. [DOI] [PubMed] [Google Scholar]
  5. LAURELL C. B. ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS. Anal Biochem. 1965 Feb;10:358–361. doi: 10.1016/0003-2697(65)90278-2. [DOI] [PubMed] [Google Scholar]
  6. Martin A., Lachmann P. J., Halbwachs L., Hobart M. J. Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry. 1976 Apr;13(4):317–324. doi: 10.1016/0019-2791(76)90341-4. [DOI] [PubMed] [Google Scholar]
  7. Miller G. W., Nussenzweig V. Complement as a regulator of interactions between immune complexes and cell membranes. J Immunol. 1974 Aug;113(2):464–469. [PubMed] [Google Scholar]
  8. Miller G. W., Saluk P. H., Nussenzweig V. Complement-dependent release of immune complexes from the lymphocyte membrane. J Exp Med. 1973 Sep 1;138(3):495–507. doi: 10.1084/jem.138.3.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Oldstone M. B., Dixon F. J. Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med. 1969 Mar 1;129(3):483–505. doi: 10.1084/jem.129.3.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Perrin L. H., Lambert P. H., Miescher P. A. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest. 1975 Jul;56(1):165–176. doi: 10.1172/JCI108065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Smith M. D., Barratt T. M., Hayward A. R., Soothill J. F. The inhibition of complement-dependent lymphocyte rosette formation by the sera of children with steroid-sensitive hephrotic syndrome and other renal diseases. Clin Exp Immunol. 1975 Aug;21(2):236–243. [PMC free article] [PubMed] [Google Scholar]
  12. Soothill J. F., Steward M. W. The immunopathological significance of the heterogeneity of antibody affinity. Clin Exp Immunol. 1971 Aug;9(2):193–199. [PMC free article] [PubMed] [Google Scholar]
  13. Spitzer R. E., Stitzel A. E. Inhibition of C3 conversion after allotransplantation. Transplantation. 1972 Feb;13(2):116–126. doi: 10.1097/00007890-197202000-00010. [DOI] [PubMed] [Google Scholar]
  14. Spitzer R., Stitzel A., Florio L., Urmson J. Inhibition of the alternative pathway of complement activation by a serum factor generated during transplant rejection. Immunochemistry. 1976 May;13(5):395–400. doi: 10.1016/0019-2791(76)90374-8. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES